Hui Shao

1.2k total citations · 1 hit paper
29 papers, 827 citations indexed

About

Hui Shao is a scholar working on Hepatology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hui Shao has authored 29 papers receiving a total of 827 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hepatology, 6 papers in Epidemiology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hui Shao's work include Glaucoma and retinal disorders (5 papers), Corneal surgery and disorders (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Hui Shao is often cited by papers focused on Glaucoma and retinal disorders (5 papers), Corneal surgery and disorders (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Hui Shao collaborates with scholars based in China, United States and Japan. Hui Shao's co-authors include Ping-Yu Lee, Wendy Verret, Ann‐Lii Cheng, Lindong Li, Masatoshi Kudo, Philippe Merle, Juan Liu, Masafumi Ikeda, Peter R. Galle and В. В. Бредер and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Ophthalmology.

In The Last Decade

Hui Shao

28 papers receiving 814 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

2021 229 citations Masatoshi Kudo, Philippe Merle et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hui Shao China	16	349	246	174	159	146	29	827
Qiang Ji China	16	91 0.3×	100 0.4×	13 0.1×	84 0.5×	125 0.9×	57	674
Carolina Armengol Spain	18	181 0.5×	172 0.7×	8 0.0×	74 0.5×	211 1.4×	32	940
Kanji Wakabayashi Japan	15	628 1.8×	105 0.4×	15 0.1×	21 0.1×	522 3.6×	21	935
Siu–Tsan Yuen China	16	437 1.3×	124 0.5×	8 0.0×	94 0.6×	551 3.8×	16	1.1k
Phillips Mj Canada	19	280 0.8×	241 1.0×	15 0.1×	48 0.3×	165 1.1×	38	853
Jinpiao Lin China	14	240 0.7×	140 0.6×	6 0.0×	21 0.1×	270 1.8×	32	701
Minjie Mao China	13	74 0.2×	231 0.9×	7 0.0×	30 0.2×	230 1.6×	38	702
Hsiang‐Ju Lin Taiwan	13	638 1.8×	181 0.7×	4 0.0×	123 0.8×	456 3.1×	21	1.0k
Nick Shackel Australia	9	172 0.5×	38 0.2×	10 0.1×	25 0.2×	165 1.1×	12	432
Guang Song China	14	48 0.1×	58 0.2×	14 0.1×	17 0.1×	69 0.5×	24	654

Countries citing papers authored by Hui Shao

Since Specialization

Citations

This map shows the geographic impact of Hui Shao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Shao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Shao more than expected).

Fields of papers citing papers by Hui Shao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui Shao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Shao. The network helps show where Hui Shao may publish in the future.

Co-authorship network of co-authors of Hui Shao

This figure shows the co-authorship network connecting the top 25 collaborators of Hui Shao. A scholar is included among the top collaborators of Hui Shao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui Shao. Hui Shao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shao, Hui. (2025). Corneal biomechanical properties in myopic anisometropia measured by corneal visualization scheimpflug technology. American Journal of Translational Research. 17(4). 2817–2825.

Chen, Shanshan, Lu Huang, Yong S. Chu, et al.. (2025). Noninvasive diagnosis model for predicting significant liver inflammation in patients with chronic hepatitis B in the immune-tolerant phase. Scientific Reports. 15(1). 3031–3031. 1 indexed citations

Shao, Hui, Jingyan Chen, Ali Li, et al.. (2023). Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. Applied Biochemistry and Biotechnology. 195(8). 5217–5237. 18 indexed citations

Wirta, David, Yasuaki Kuwayama, Fenghe Lu, Hui Shao, & Noriko Odani‐Kawabata. (2022). Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study. Journal of Ocular Pharmacology and Therapeutics. 38(3). 240–251. 9 indexed citations

Yang, Yanyan, Shanshan Li, Xueting Xie, et al.. (2022). Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients. Frontiers in Public Health. 9. 784718–784718. 4 indexed citations

Shao, Hui, et al.. (2021). The Mechanism of miR-141 Regulating the Proliferation and Metastasis of Liver Cancer Cells by Targeting STAT4. Journal of Oncology. 2021. 1–9. 11 indexed citations

Qin, Shukui, Zhenggang Ren, Yin‐Hsun Feng, et al.. (2021). Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer. 10(4). 296–308. 81 indexed citations

Shemesh, Colby S., Phyllis Chan, Hui Shao, et al.. (2021). Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. Liver Cancer. 10(5). 485–499. 16 indexed citations

Beckers, Henny J. M., Florent Aptel, Carroll A.B. Webers, et al.. (2021). Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma. Ophthalmology Glaucoma. 5(2). 195–209. 87 indexed citations

10.

Xian, Jianchun, et al.. (2021). Effect of portal vein thrombosis on the prognosis of patients with cirrhosis without a liver transplant. Medicine. 100(16). e25439–e25439. 17 indexed citations

11.

Toh, Han Chong, Philippe Merle, Kaoru Tsuchiya, et al.. (2020). O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150. Annals of Oncology. 31. 234–234. 12 indexed citations

12.

Yu, A‐Yong, Hui Shao, An-Peng Pan, et al.. (2020). Corneal biomechanical properties in myopic eyes evaluated via Scheimpflug imaging. BMC Ophthalmology. 20(1). 279–279. 19 indexed citations

13.

Li, Shijian, et al.. (2020). Taizhou’s COVID-19 prevention and control experience with telemedicine features. Frontiers of Medicine. 14(4). 506–510. 8 indexed citations

14.

Liu, Zhisheng, et al.. (2019). Neferine inhibits MDA-MB-231 cells growth and metastasis by regulating miR-374a/FGFR-2. Chemico-Biological Interactions. 309. 108716–108716. 21 indexed citations

15.

Pishvaian, Michael J., Baek‐Yeol Ryoo, Stacey Stein, et al.. (2018). Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Annals of Oncology. 29. viii718–viii719. 62 indexed citations

16.

Xu, Wenfang, et al.. (2016). CD127 Expression in Naive and Memory T Cells in HIV Patients Who Have Undergone Long-Term HAART. Laboratory Medicine. 48(1). 57–64. 15 indexed citations

17.

Sun, Jianhua, et al.. (2016). [EXPERIMENTAL STUDY ON THREE DIMENSINONAL CULTURE OF RABBIT ANNULUS FIBROSUS CELLS ON KLD-12 POLYPEPTIDE NANOFIBER GEL IN VlTRO].. PubMed. 30(3). 303–8. 1 indexed citations

18.

Shao, Hui, et al.. (2011). [Expressions of HIF-α and its target gene in monochorionic twin placentas with twin-twin transfusion syndrome].. PubMed. 43(6). 792–7. 3 indexed citations

19.

Shao, Hui. (2007). The protecting effects of totalflavonoids of astragalus (TFA) on experimental arrhythmia in rats. 1 indexed citations

20.

Lee, Ping-Yu, et al.. (1988). The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects.. PubMed. 29(10). 1474–7. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact